Journal Section:
Editorial
References
1.
Cao
Z
. Causal relationships between gut microbiotas, blood metabolites, and neuroendocrine tumors: a mediated Mendelian randomization study
. Neuroendocrinology
. 2024
;114
(11
):981
–992
.2.
Massironi
S
, Sciola
V
, Peracchi
M
, Ciafardini
C
, Spampatti
MP
, Conte
D
. Neuroendocrine tumors of the gastro-entero-pancreatic system
. World J Gastroenterol
. 2008
;14
(35
):5377
–84
. 3.
Fraenkel
M
, Kim
M
, Faggiano
A
, de Herder
WW
, Valk
GD
; Knowledge NETwork
. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature
. Endocr Relat Cancer
. 2014
;21
(3
):R153
–63
. 4.
Boyar Cetinkaya
R
, Aagnes
B
, Thiis-Evensen
E
, Tretli
S
, Bergestuen
DS
, Hansen
S
. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010
. Neuroendocrinology
. 2017
;104
(1
):1
–10
. 5.
Dasari
A
, Shen
C
, Halperin
D
, Zhao
B
, Zhou
S
, Xu
Y
, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
. JAMA Oncol
. 2017
;3
(10
):1335
. 6.
Das
S
, Dasari
A
. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences
. Curr Oncol Rep
. 2021
;23
(4
):43
. 7.
Rossi
RE
, Massironi
S
. The increasing incidence of neuroendocrine neoplasms worldwide: current knowledge and open issues
. J Clin Med
. 2022
;11
(13
):3794
. 8.
Sanguedolce
F
, Zanelli
M
, Palicelli
A
, Cavazza
A
, De Marco
L
, Zizzo
M
, et al. The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs
. Panminerva Med
. 2022
;64
(2
):259
–64
. 9.
Boyar Cetinkaya
R
, Aagnes
B
, Myklebust
T
, Thiis-Evensen
E
. Survival in neuroendocrine neoplasms; a report from a large Norwegian population-based study
. Int J Cancer
. 2018
;142
(6
):1139
–47
. 10.
Alexandraki
KI
, Spyroglou
A
, Kykalos
S
, Daskalakis
K
, Kyriakopoulos
G
, Sotiropoulos
GC
, et al. Changing biological behaviour of NETs during the evolution of the disease: progress on progression
. Endocr Relat Cancer
. 2021
;28
(5
):R121
–40
. 11.
Feola
T
, Centello
R
, Sesti
F
, Puliani
G
, Verrico
M
, Di Vito
V
, et al. Neuroendocrine carcinomas with atypical proliferation index and clinical behavior: a systematic review
. Cancers
. 2021
;13
(6
):1247
. 12.
Zhang
Z
, Li
D
, Xie
F
, Muhetaer
G
, Zhang
H
. The cause-and-effect relationship between gut microbiota abundance and carcinoid syndrome: a bidirectional Mendelian randomization study
. Front Microbiol
. 2023
;14
:1291699
. 13.
Mulders
MCF
, Audhoe
AS
, Van Koetsveld
PM
, Feelders
RA
, Hofland
LJ
, de Herder
WW
, et al. Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature
. Eur J Cancer
. 2024
;197
:113472
. 14.
Zhang
CY
, Jiang
SJ
, Cao
JJ
, Xu
Y
, Wang
XY
, Li
R
, et al. Investigating the causal relationship between gut microbiota and gastroenteropancreatic neuroendocrine neoplasms: a bidirectional Mendelian randomization study
. Front Microbiol
. 2024
;15
:1420167
. 15.
Sepich-Poore
GD
, Zitvogel
L
, Straussman
R
, Hasty
J
, Wargo
JA
, Knight
R
. The microbiome and human cancer
. Science
. 2021
;371
(6536
):eabc4552
. 16.
Picardo
SL
, Coburn
B
, Hansen
AR
. The microbiome and cancer for clinicians
. Crit Rev Oncol Hematol
. 2019
;141
:1
–12
. 17.
Sharma
VR
, Singh
M
, Kumar
V
, Yadav
M
, Sehrawat
N
, Sharma
DK
, et al. Microbiome dysbiosis in cancer: exploring therapeutic strategies to counter the disease
. Semin Cancer Biol
. 2021
;70
:61
–70
. 18.
González-Sánchez
P
, DeNicola
GM
. The microbiome(s) and cancer: know thy neighbor(s)
. J Pathol
. 2021
;254
(4
):332
–43
. 19.
Wong-Rolle
A
, Wei
HK
, Zhao
C
, Jin
C
. Unexpected guests in the tumor microenvironment: microbiome in cancer
. Protein Cell
. 2021
;12
(5
):426
–35
. 20.
Chen
Y
, Wu
FH
, Wu
PQ
, Xing
HY
, Ma
T
. The role of the tumor microbiome in tumor development and its treatment
. Front Immunol
. 2022
;13
:935846
. 21.
Zhou
X
, Kandalai
S
, Hossain
F
, Zheng
Q
. Tumor microbiome metabolism: a game changer in cancer development and therapy
. Front Oncol
. 2022
;12
:933407
. 22.
Rajagopala
SV
, Vashee
S
, Oldfield
LM
, Suzuki
Y
, Venter
JC
, Telenti
A
, et al. The human microbiome and cancer
. Cancer Prev Res
. 2017
;10
(4
):226
–34
. 23.
Hu
W
, Chen
ZM
, Li
XX
, Lu
L
, Yang
GH
, Lei
ZX
, et al. Faecal microbiome and metabolic signatures in rectal neuroendocrine tumors
. Theranostics
. 2022
;12
(5
):2015
–27
. 24.
Vitale
G
, Dicitore
A
, Barrea
L
, Sbardella
E
, Razzore
P
, Campione
S
, et al. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: are we on the highway to hell
. Rev Endocr Metab Disord
. 2021
;22
(3
):511
–25
. 25.
Massironi
S
, Facciotti
F
, Cavalcoli
F
, Amoroso
C
, Rausa
E
, Centonze
G
, et al. Intratumor microbiome in neuroendocrine neoplasms: a new partner of tumor microenvironment? A pilot study
. Cells
. 2022
;11
(4
):692
. 26.
Mohamed
A
, Asa
SL
, McCormick
T
, Al-Shakhshir
H
, Dasari
A
, Mauricio
R
, et al. The role of the microbiome in gastroentero-pancreatic neuroendocrine neoplasms (GEP-NENs)
. Curr Issues Mol Biol
. 2022
;44
(5
):2015
–28
. 27.
Kiousi
DE
, Kouroutzidou
AZ
, Neanidis
K
, Karavanis
E
, Matthaios
D
, Pappa
A
, et al. The role of the gut microbiome in cancer immunotherapy: current knowledge and future directions
. Cancers
. 2023
;15
(7
):2101
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended...
© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.